The Future of Healthcare: LifeQ, the provider of biometrics and health information derived from wearable devices

Laurie Olivier, the Chief Executive Officer of LifeQ, the leading independent provider of biometrics and health information derived from wearable devices used in world leading health management solutions joins eHealth Radio and the Healthcare and Technology Channels.

Listen to interview with host Eric Michaels and guest Laurie Olivier discuss the following:

1. You bring over three decades of global technology and business leadership as CEO and founder of LifeQ, and you have served on the boards of more than 50 startup, private and public companies around the world. Tell us about yourself, and how you founded LifeQ.
2. What is LifeQ’s mission, and what does it do that is currently not being done?
3. Tell us about the biggest pain points when it comes to the digital aspect of healthcare, as well as your outlook on health and wellness technology.
4. How is LifeQ sequencing its coverages of the cardiovascular, respiratory, sleep, fitness, mental, musculoskeletal, renal and other areas?
5. How do you foresee LifeQ fitting into the future of healthcare and the overall health and wellness of people who use it?

Laurie Olivier is the Chief Executive Officer of LifeQ, the leading independent provider of biometrics and health information derived from wearable devices used in world leading health management solutions. Mr. Olivier leads the firm’s growth and overall vision, including investment, strategy and partnerships with global leaders in wearables, silicon manufacturers, digital platforms, and insurance companies — leading the movement toward improving health and wellness around the world.

Mr. Olivier brings over three decades of global technology and business leadership, thirty years of venture capital and private equity experience, and has served on the boards of more than 50 startup, private and public companies around the world, including the largest industrial conglomerate in South Africa. As the Atlanta-based partner of 4Di Capital, the South African based early-stage venture capital management firm, and the US-based partner of Veritas Venture Partners, a pioneering seed stage Israeli VC firm, Mr. Olivier is passionate about developing new technologies into startups that positively impact people and society.

Founded in 2014, LifeQ has two key value propositions: enable wearable devices to provide business and near clinical-grade health information streams; and generate health and wellness solutions for consumer, business and clinical applications.

Mr. Olivier earned his Bachelor of Science in Electronics Engineering from the University of Pretoria; a Bachelor of Commerce in Finance and Strategic Marketing; and a Diploma in Datametrics and Operational Research from the University of South Africa. Mr. Olivier’s work has been recognized by Dow Jones Venture Reporter, the Atlanta Journal Constitution, and the American Israel Chamber of Commerce. A native of Groot Marico, South Africa, Mr. Olivier lives in Atlanta with his wife.

Website: https://lifeq.com 

Social Media Links:
LinkedIn: https://linkedin.com/company/lifeq  
Facebook: https://facebook.com/lifeqinc 
Instagram: https://instagram.com/lifeqinc  
Twitter: https://twitter.com/lifeqinc 

Céline Fournier, PhD, Chief Medical Officer, Echosens Discusses the Clinical Evidence and Future of Liver Screening Technology

Céline Fournier, PhD, the Chief Medical Officer of Echosens, a high-technology company offering the FibroScan family of products, joins eHealth Radio and the Health News and Technology Channels to discuss the robust clinical data FibroScan has and Echosens plan to continue building clinical evidence.

Listen to interview with host Eric Michaels and guest Dr. Céline Fournier discuss the following:

1. Could you tell us about the robust level of evidence FibroScan has and how many communications and guidelines recommend the value of FibroScan?
2. What is Echosens plan to continue building clinical evidence?
3. How might existing research on FibroScan impact NAFLD/NASH drug development?
4. If you were to look into the future when the drugs for fibrotic NASH become available, how do you see FibroScan best supporting clinical practice for managing patients on treatment?
5. Could you tell us about the clinical data strategy Echosens has in place and what long term goals you anticipate?

Céline Fournier, PhD, age 45, is presently Chief Medical Officer of Echosens (Paris, France). She graduated from University of Technology of Compiègne Engineering School (France) in Bioengineering in 1998. During the course of her engineering training, she studied one year at the University of Pennsylvania (Philadelphia, USA). She then went to the Laboratory of Parametric Imaging (Paris, France) to work on skin tissue characterization by ultrasound and defended her PhD in Bioengineering in 2002. She joined Echosens a few months later as Medical Affairs Manager to conduct the first multicenter clinical trial to validate the diagnosis performances of FibroScan. In 2012, she became Medical and Regulatory Affairs Director. As CMO since 2017, she is globally responsible for Clinical Operation, Medical Affairs as well as Clinical Application and Training.

About Echosens

Echosens, the developer of FibroScan®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 2,500 peer-reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans.

Website: https://echosens.com

Social Media Links:
Facebook: facebook.com/fibroscan.echosens 
Linkedin: linkedin.com/company/echosens 
Youtube: youtube.com/user/EchosensTV
Twitter: twitter.com/Echosens

How Digital Technology is Changing the Landscape of Elder Health Care

Avanlee Christine, the CEO and Founder of Avanlee Care, a new app that improves how families communicate and manage their care receiver’s health in real time joins eHealth Radio and the Senior Care and Technology Channels.

Listen to interview with host Eric Michaels and guest Avanlee Christine discuss the following:

1. Tell me about the Avanlee Elderly Care APP and how it is different than what is currently on the market?
2. What is the most important feature of the Avanlee Care APP?
3. What are the challenges of caring for an aging parent or relative?
4. How has digital technology improved elder care and what does the future hold in your opinion?
5. What does the future hold for senior care in America?

Avanlee Christine is a founder, technologist and businesswoman. Throughout her career Avanlee has worked to provide better health and social care solutions for the elderly. Her experience caring for others and working with her own family to care for her ailing grandfather for 8 years, led her to realize that there was no technology solution available on the market that helped families and care-givers effectively support the health and social needs of an aging relative remotely. With the pandemic that need became all the more acute. She founded Avanlee Care to address that gap and provide families with a solution to transform the quality of remote health and social care for their elderly relatives.

Website: AvanleeCare.com 

Social Media Links:
Facebook: facebook.com/AvanleeCare
Instagram: instagram.com/avanlee_care
Twitter: twitter.com/avanleec

The Pursuit of Cleanliness: Pristine Potty App for a Better Restaurant Experience

Michael Gamble, CEO and Creator of Pristine Potty App that helps consumers rate the restrooms of their favorite dining spots joins eHealth Radio and the Hygiene & Mobile App Channels.

Listen to interview with host Eric Michaels and guest Michael Gamble discuss the following:

1. Where did the idea for Pristine Potty come from? What is the mission for the app?
2. How does Pristine Potty offer customer and restaurant satisfaction?
3. What are the three simple criteria for the proprietary rating system?
4. How do you plan on growing Pristine Potty?
5. Where can you find Pristine Potty?

Pristine Potty was created as a phone application to help consumers rate the restrooms of their favorite dining spots. With CEO and Creator, Michael A. Gamble’s goal of creating better service for dining experiences. Pristine Potty’s mission is to help restaurants elevate their service and raise dining standards all over the world. In an age of pandemic unrest and hygiene consciousness, the Pristine Potty app is dedicated to being the authority on pristine standards for an enjoyable experience. Pristine Potty is available for free download at the Apple App Store and Google Play Store.

Website: https://pristinepotty.com

Social Media Links:
Facebook: facebook.com/pristinepotty
Instagram: instagram.com/pristinepotty
Twitter: twitter.com/pristine_potty

The evolving role of digital AI companions in at-home healthcare

Dor Skuler, the CEO & Co-Founder at Intuition Robotics, which creates empathetic digital companions that positively impact people's lives joins eHealth Radio and the Senior Care & Technology Channels.

The company's first product, ElliQ, is an artificial intelligence driven proactive social robot for older adults to keep them healthy, active, and independent at home, bridging the gap between them and their healthcare providers.

Listen to interview with host Eric Michaels and guest Dor Skuler discuss the following:

1. What is ElliQ and how did you develop the technology?
2. How have companion robots been affecting seniors' health and well-being at home and how have they evolved over the past several years?
3. Why did you decide to expand into healthcare during COVID and what did you learn that led to this pivot in strategy?
4. What impact do you think ElliQ will have on the healthcare field?
5. What role should digital companions play in the grander healthcare market and challenges doctors face in patient communication?

Conclusion: To help older adults age independently at home for as long as possible, consider a proactive digital companion that can help efficiently connect them to the world, their families, and their healthcare teams.

As a serial entrepreneur, Dor Skuler has co-founded five ventures, the most recent being Intuition Robotics, following his passion to develop artificial intelligence-driven robotics that address major social issues of the 21st century.

Having trained in Israel’s elite military intelligence unit 8200, Dor made a mark on interactive broadcast technology with Zing Interactive Media (acquired by Invesco, NASDAQ: IVZ) and security software through Safend (acquired by Wave Systems Corp, NASDAQ: WAVX). Dor then joined Alcatel-Lucent (NYSE:ALU) to create and lead innovative ventures, most notably as Founder and GM of Cloudband, the world’s first platform for Network Functions Virtualization (NFV), cited by Nokia as a major motive to purchasing the French-American telecoms giant. As Senior Vice President at Alcatel-Lucent, Dor was a regular speaker on the telecoms circuit, frequently cited in the media and made the Global Telecom Business ’40 under 40’ list in 2009, 2011 and 2013. Dor also served as Vice President of Strategy and Global Head of Corporate Development for Alcatel-Lucent in its corporate headquarters in Paris.

Dor holds an MBA and Master’s of Science in Marketing from Temple University, has co-authored ‘Cloud Computing: Business Trends and Technologies’ published by Wiley in 2016 and holds board level advisory and director roles for several telecoms, cyber security and tech-led social impact ventures.

Websites: intuitionrobotics.com  | elliq.com

Social Media Links:
Facebook: facebook.com/elliqsidekick 
Instagram: instagram.com/elliqsidekick 
Twitter: twitter.com/intuitionrobo

Hispanic Heritage Month: Dr. Juan Pablo Frias, M.D. Discusses the Role of FibroScan for Clinical Research Programs

Dr. Juan Pablo Frias, M.D., Medical Director, National Research Institute joins eHealth Radio and the Health News and Technology Channels to discuss the role of FibroScan for clinical research programs, addressing racial disparities and improving patient management and outcomes.

Listen to interview with host Eric Michaels and guest Dr. Juan Pablo Frias discuss the following:

1. How has FibroScan impacted your clinical research programs at National Research Institute?
2. What role does FibroScan play for groups looking to get into this research? How does it factor into their participation?
3. As an endocrinologist looking to the future when the drugs for NASH become available, how do you see FibroScan best supporting clinical practice for managing patients on treatment?
4. What is the ethnic competition of your patient population? Is having access to FibroScan important for this population, or access to healthcare services in general?
5. Where do you see this going in terms of management and improving outcomes?

Dr. Frias, a native of Chile, completed his undergraduate studies at the University of Florida and received his medical degree from Vanderbilt University School of Medicine. After serving 5 years as a General Medical Officer in the US Navy, he completed his training in Internal Medicine at Vanderbilt University and the University of Tennessee, and his Fellowship in Endocrinology, Diabetes and Metabolism at the University of California, San Diego.

Dr. Frías has held leadership positions in Clinical and Medical Affairs at Eli Lilly, Amylin Pharmaceuticals, Pfizer, and Johnson and Johnson, where he served as Chief Medical Officer and Global Vice President of Clinical and Medical Affairs, Diabetes Care.

Dr. Frías has held academic positions at the University of Colorado Health Sciences Center, Barbara Davis Center for Diabetes, and the University of California San Diego School of Medicine, where he is currently on the clinical faculty. He is also active in the non-profit organization Taking Control of Your Diabetes (TCOYD), where he lectures at the organization’s Latino Initiative patient conferences and provides continuing medical education for healthcare providers. Dr. Frías has been involved in diabetes and metabolism-related research for over 15 years and has authored numerous publications in this field.

Website: https://echosens.com

Social Media Links:
Facebook: facebook.com/fibroscan.echosens 
Linkedin: linkedin.com/company/echosens 
Youtube: youtube.com/user/EchosensTV
Twitter: twitter.com/Echosens

New Charitable App Promotes “Active Aging”

Joe Liu, Founder of the Joe & Emmy Liu Charitable Foundation and developer of Lively Health, the first charitable self-directed lifestyle conditioning App for prevention of chronic conditions and active aging joins eHealth Radio and the Health News and Technology Channels.

Listen to interview with host Eric Michaels and guest Joe Liu discuss the following:

1. What was the impetus behind the creation of the Lively Health app?
2. What separates Lively Health from all the other “wellness” apps on the market?
3. You say your app promotes the concept of “active aging.” Can you explain exactly what that is and why it’s important?
4. It’s been proven that people in lower socioeconomic groups have less access to quality health care and are more susceptible to chronic medical conditions? Is that why you made the app free for download?
5. Your app takes a very holistic approach, asking the user to not only answer questions about their physical health but also their social, financial and psychological status. Do you feel that the medical establishment doesn’t place enough emphasis on these so-called “peripheral” areas when evaluating a person’s overall health?

Joe Liu is a Silicon Valley serial entrepreneur, who started the Joe & Emmy Liu Foundation with a vision to benefit humanity with his entrepreneurial and technical expertise. Liu started his first company Techlink Co. in 1984. He then co-founded Oplink Communications in 1995, led the IPO in 2000, and acquisition by Molex/Koch Industries in 2014. Liu angel invested in numerous high-tech companies, guided them to successful exits, and contributed tremendously to the growth of IT industry. Joe and his wife Emmy started The Joe and Emmy Liu Family Foundation in 2019, as a 501(c)3 private operating foundation using technology innovation to benefit human well-being.

Website: https://livelyhealth.org

Social Media Links:
Facebook: facebook.com/Livelyhealthfoundation
Linkedin: linkedin.com/company/livelyhealthfoundation
Instagram: instagram.com/livelyhealthfoundation
Twitter: twitter.com/livelyhealthapp

July 28 is World Hepatitis Day: The Role of FibroScan to Cure HCV Among Veterans

Dustin Lee, Owner and President of Fidelis Sustainability Distribution, LLC, USMC scout sniper veteran and principal joins eHealth Radio and the Health News and Technology Channels to discuss the role FibroScan technology has played in curing hepatitis C virus (HCV) among the Department of Veterans Affairs (VA).

Listen to interview with host Eric Michaels and guest Dustin Lee discuss the following:

1. What are the challenges of treating liver disease among veterans?
2. What is the connection between hepatitis C virus (HCV) and nonalcoholic fatty liver disease (NAFLD)?
3. How did the VA eradicate HCV among veterans?
4. Why is FibroScan the VA’s liver assessment tool of choice, and how many VA Hospitals have purchased FibroScan?
5. What are the benefits of FibroScan for physicians treating veterans?

Fidelis, LLC is a certified Service-Disabled Veteran Owned Small Business as well as a U.S. Small Business Administration certified Small Disadvantaged Business (8(a)) company. Fidelis provides a wide variety of services for the Federal, State, and Local government nationwide as well as overseas.

Echosens, the developer of FibroScan®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 2,500 peer-reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans.

Website: https://echosens.com

Social Media Links:
Facebook: facebook.com/fibroscan.echosens 
Linkedin: linkedin.com/company/echosens 
Youtube: youtube.com/user/EchosensTV
Twitter: twitter.com/Echosens

Douglas Dieterich, M.D., discusses role of FibroScan in the diagnoses of chronic liver disease

Douglas Dieterich, M.D., director of the Institute for Liver Medicine, Mount Sinai Health System, and professor of medicine for the Division of Liver Disease, Icahn School of Medicine at Mount Sinai joins eHealth Radio and the Health News and Technology Channels to discuss noninvasive liver screening to halt the progression of liver disease.

Listen to interview with host Eric Michaels and guest Dr. Douglas Dieterich discuss the following:

1. Please share with us the importance of ongoing assessment of liver stiffness and fat as part of a liver health assessment?
2. What role does FibroScan play in the diagnoses of chronic liver diseases and cirrhosis?
3. What is the risk of hepatocellular carcinoma (HCC) in people with long-term liver diseases, and if the liver is scarred by infection with hepatitis B or hepatitis C?
4. Tell us more about the use of FibroScan in hospital settings to improve outcomes and reduce costs in the assessment of liver disease.
5. Where do you see this going in terms of management and improving outcomes?

Dr. Douglas Dieterich is currently Professor of Medicine in the Division of Liver Diseases and also Director of Continuing Medical Education in the Department of Medicine at Mount Sinai School of Medicine, New York, NY.

He has a triple appointment in the divisions of Liver Disease, Gastroenterology, and Infectious Diseases.

Douglas T. Dieterich graduated from Yale University in New Haven, CT and received his Doctorate of Medicine from New York University of Medicine in NY. He completed his internship and residency in Internal Medicine at the Bellevue Hospital Center in New York, NY where he was also a fellow in the Division of Gastroenterology. He became Clinical Assistant Professor of medicine and then a Clinical Professor of Medicine, both at the New York University. He remains as an Adjunct Clinical Professor of Medicine at New York University School of Medicine.

Dr. Dieterich is an investigator for many ongoing clinical trials evaluating the safety and efficacy of new antiviral treatments for chronic hepatitis B & C.

Dr. Dieterich is a member of many professional societies and is a fellow of both the American College of Physicians and the American College of Gastroenterology. He has served on several committees of the AIDS Clinical Trials Group at the National Institutes of Health (NIH), including the Steering Committee of the Opportunistic Infections Core Committee and the Cytomegalovirus (CMV) Committee. He was Chair and Co-Chair, respectively, of the Enteric Parasites Committee and the Protozoan Committee. He also served on the NIH Study Sections for CMV and cryptosporidiosis.

Widely published, Dr. Dieterich is the author of numerous journal articles, abstracts and book chapters on viral hepatitis and AIDS associated infections of the gastrointestinal tract and liver.

Website: https://echosens.com

Social Media Links:
Facebook: facebook.com/fibroscan.echosens 
Linkedin: linkedin.com/company/echosens 
Youtube: youtube.com/user/EchosensTV
Twitter: twitter.com/Echosens

Echosens CEO Discusses How Company Helps Fight Liver Disease Epidemic

Jon Gingrich, the CEO of Echosens North America, a high-technology company offering the FibroScan family of products joins eHealth Radio and the Health News & Technology Channels.

Listen to interview with host Eric Michaels and guest Jon Gingrich discuss the following:

1. Please share with us the ongoing need for liver health assessment – and why the detection of fatty liver disease remains such a pressing challenge for Americans.

2. Please tell our audiences about the 2021 Echosens corporate initiatives and its focus on halting the progression of non-alcoholic fatty liver disease (NAFLD), fibrosis and cirrhosis. Describe new goals and objectives for building on the progress that Echosens has made in 2020.
3. Explain how Echosens plans to further expand the use of FibroScan technology in healthcare systems across America.

4. Can you describe specific programs and services to help educate specialists on the role of FibroScan?

5. How is Echosens helping payers and employers to understand the value of FibroScan?

6. Tell us about Echosens’ FAST score implementation and what successes you are seeing as a result of its use.

7. Explain how the COVID-19 pandemic has highlighted opportunities for Echosens to solve new problems, and support innovations that advance preventive care, address critical health care needs and improve outcomes for more Americans.
8. What is Echosens’ focus to continue bringing this awareness of NAFLD diagnosis and treatment in a post-pandemic world?

About Jon Gingrich, CEO, Echosens North America

With more than 20 years of global medical device and health care sales, marketing and general management experience at AxoGen, Inc., Hologic, Inc., Boston Scientific Corporation and Unilever, N.V, Gingrich now leads the development and execution of the Echosens U.S. strategy for expanding the utilization of FibroScan® technology in the assessment of chronic liver disease. As a member of the broader global executive leadership team, he works to implement the Company’s transformation plan and shape the future of Echosens.

About Echosens

Echosens, the developer of FibroScan®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 2,500 peer-reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans.

Website: https://echosens.com

Social Media Links:
Facebook: facebook.com/fibroscan.echosens 
Linkedin: linkedin.com/company/echosens 
Youtube: youtube.com/user/EchosensTV